TA263 Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer: review proposal - June 2015

Proposal to move the existing guidance to the static list

The planned date for review of the above guidance is June 2015.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

No new evidence has been identified that is likely to lead to a change in the existing recommendations. 

Consequently we propose that TA263 should move to the ‘static list’ of technology appraisals.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

Should the clinical guideline for Advanced breast cancer: Diagnosis and treatment (CG81) be updated in the future, then any new clinical guideline would be able to incorporate the recommendations made in TA263.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.

Please see appendix A for a full list of the organisations we have contacted. 

June 2015

This page was last updated: 25 June 2015